2020 Year-End NASH Review 1: Drugs and Diagnostics

The Surfers and guests Vlad Ratziu and Mazen Noureddin discuss key lessons learned in 2020 about Drugs and Diagnostics

Vlad Ratziu and Mazen Noureddin join the Surfers to explore some of the key lessons learned and issues uncovered in 2020. Vlad Ratziu provides a 10-minute overview of a fast-paced year of successes (and occasional failures) in clinical trials and novel diagnostics. Mazen Noureddin discusses the expanding role of non-invasive liver tests in diagnosis, patient treatment and monitoring and drug development. Stephen Harrison updates our knowledge about the use of clinical endpoints in obtaining conditional drug approvals. Finally, Roger Green places the entire year in a systems context with an eye toward the Law of Unintended Consequences and why the obeticholic acid Complete Response Letter was not the death knell many observers feared.

listen to each segment…

Request A Transcript of This Episode
Request Transcript

Join The Discussion…

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"